BillionToOne
Business Services · California, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
1035 Obrien Dr, Menlo Park, California, ...Phone Number
(650) 460-2551Website
www.billiontoone.comRevenue
$354.5 MillionStock Symbol
BLLNIndustry
ZI Rank: 2
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
5
4
1
2
2
About BillionToOne
BillionToOne, headquartered in Menlo Park, California, is a precision diagnostics company with a mission to make molecular diagnostics more accurate, efficient, and accessible for all. The company's patent-pending QCT molecular counter platform is the only technology platform that can accurately count DNA molecules to the single-count level. BillionToOne's flagship product, UNITY, is the first and only noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis (CF), spinal muscular atrophy (SMA), and hemoglobinopathies through maternal blood.Explore more
BillionToOne Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BillionToOne your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once BillionToOne has new funding data
Product Launch: Get notified when BillionToOne launches new products
BillionToOne, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at BillionToOne
Click to see if BillionToOne had a recent Job posting/layoffs
Check if BillionToOne has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on BillionToOne recently announced quarterly report
Check out if BillionToOne is spiking on competitors!
Recommended Actions
Find VP level buyers at BillionToOne
Find more new buyers
Compare Similar Companies to BillionToOne
Compare insights from companies similar to BillionToOne, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$12.9M
201-500
Private
-
2000
Company Profile Activity
Activity Insights
BillionToOne is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
BillionToOne is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about BillionToOne.
BillionToOne financials insights
Gather financial insights about BillionToOne, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$15M
2021
Series B
$55M
2022
Series C
$125M
Unspecified
$48.5M
2024
Series D
$130M
2025
IPO
$273.1M
BillionToOne Tech Stack
A closer look at the technologies used by BillionToOne
Most Recent Scoops
Open Position
Open Position
Open Position
Person-Based
Stake & Stock Ownership, Finance
Open Position
BillionToOne News & Media
BillionToOne's Northstar Response® Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer-Reviewed Study
Tissue-free ctDNA monitoring was the dominant independent predictor of survival across 12 tumor types and two prospective cohorts MENLO PARK, Calif., June 29, 2026 /PRNewswire/ -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create...BillionToOne (BLLN) CTO logs 20K share sale and option exercise under 10b5-1 plan
BillionToOne CTO David Tsao sold 20,000 shares around $100–$104 and exercised 20,000 options at $2.80, ending with 19,296 shares and 630,000 options outstanding, under a Rule 10b5-1 plan.BillionToOne to Participate in the William Blair 46th Annual Growth Stock Conference
MENLO PARK, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that Company management will participate in the William Blair 46th Annual Growth Stock Conference.Jim Cramer on BillionToOne: “I Say Buy It”
BillionToOne, Inc. (NASDAQ:BLLN) was among Jim Cramer’s Mad Money stock calls as he urged investors to exercise caution when it comes to red-hot AI stocks. Toward the end of the lightning round, a caller sought Cramer’s opinion on the stock, and he commented: We like BillionToOne. We looked at it, we thought the name was […]
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BillionToOne
Sign Up For FreeTo access detailed company insights
BillionToOne, headquartered in Menlo Park, California, is a precision diagnostics company with a mission to make molecular diagnostics more accurate, efficient, and accessible for all. The company's patent-pending QCT molecular counter platform is the only technology platform that can accurately count DNA molecules to the single-count level. Billio... Read More
